TRINETRA › Sectors › Healthcare
Natco Pharma Limited (NATCOPHARM) — share price, P/E and fundamentals
Natco Pharma Limited (NSE: NATCOPHARM) closed at ₹782.40 on 30 Oct 2026, -5.3% over one year, against a 52-week range of ₹773.60 – ₹1,226.80.
In the quarter ended 30 Jun 2026 (consolidated, filed 14 Aug 2026) it reported revenue of ₹735 cr and net profit of ₹207 cr, a 28.1% net margin; revenue fell 44.7% and profit fell 67.5% year on year.
On four consecutive filed quarters its trailing P/E is 12.2; since 28 May 2025 its own P/E has ranged from 7.5 to 14.1 (median 9.7), and today's reading is higher than 75% of those 352 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 9.0%, ROCE 8.5%, debt-to-equity 0.08, Piotroski F-score 4 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 92% of 63 sector peers; PBT margin higher than 75% of 63 sector peers; ROE higher than 19% of 63 sector peers.
Key figures
| Last close | ₹782.40 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -7.1% / -28.4% / -5.3% |
| 52-week low – high | ₹773.60 – ₹1,226.80 |
| Market capitalisation | ₹14,005 cr |
| Trailing P/E | 12.2 |
| Price / book | 1.52 |
| EV / EBITDA | 10.8 |
| Earnings yield | 8.2% |
| TTM EPS | ₹63.93 |
| TTM net profit | ₹1,144 cr |
| Quarter revenue | ₹735 cr |
| Quarter net profit | ₹207 cr |
| Net margin | 28.1% |
| Revenue growth (YoY) | -44.7% |
| Profit growth (YoY) | -67.5% |
| Return on equity | 9.0% |
| ROCE | 8.5% |
| Debt / equity | 0.08 |
| Current ratio | 3.01 |
| Free cash flow | ₹1,380 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹35.2 cr |
Against Healthcare peers
| Metric | NATCOPHARM | Peer median | Percentile |
|---|---|---|---|
| Net margin | 28.09 | 12.67 | 92 |
| PBT margin | 25.24 | 17.57 | 75 |
| ROE | 8.96 | 13.87 | 19 |
| ROCE | 8.46 | 17.26 | 13 |
| Debt / equity | 0.08 | 0.11 | 45 |
| Cash conversion | 1.25 | 1.25 | 50 |
| Trailing P/E | 12.24 | 43.26 | 2 |
| P/B | 1.52 | 6.02 | 0 |
Questions
What is the P/E ratio of Natco Pharma Limited?
Natco Pharma Limited's trailing P/E is 12.2, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 28 May 2025 its P/E has ranged 7.5–14.1.
What were Natco Pharma Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Natco Pharma Limited reported revenue of ₹735 cr and net profit of ₹207 cr (consolidated), filed with the exchange on 14 Aug 2026.
What is Natco Pharma Limited's ROE?
Return on equity is 9.0% based on the balance sheet dated 31 Mar 2026.
Does Natco Pharma Limited have debt?
Debt-to-equity is 0.08 on the balance sheet dated 31 Mar 2026.
What is NATCOPHARM's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, NATCOPHARM traded between ₹773.60 and ₹1,226.80.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.